Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 647-663

  Limonta, Patrizia ^a   Manea, Marilena ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Castration resistant; GnRH agonists; GnRH antagonists; GnRH receptors; GnRH based cytotoxic hybrids; GnRH II; GnRH III; Gonadotropin releasing hormone (GnRH); Prostate cancer; Targeted therapy

Indexed keywords

ABARELIX; CETRORELIX; D LYSINE GONDORELIN AGONIST; DEGARELIX; DESLORELIN; DESLORELIN DOCETAXEL BIOCONJUGATE; DOCETAXEL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GONADORELIN RECEPTOR II; GONADORELIN RECEPTOR III; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GOSERELIN; HISTRELIN; HORMONE RECEPTOR; LEUPRORELIN; LUTEINIZING HORMONE; OZARELIX; PREDNISONE; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG; ZOPTARELIN DOXORUBICIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BINDING AFFINITY; BONE DENSITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMOSOME 20; CHROMOSOME 4; CYTOTOXICITY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXON; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE RELEASE; HOT FLUSH; HUMAN; HYPOTHALAMUS; INJECTION SITE REACTION; INSULIN RESISTANCE; INTRON; LIBIDO DISORDER; MULTIPLE CYCLE TREATMENT; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OBESITY; PAIN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION;

EID: 84878921940     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.003     Document Type: Review

References (257)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 6:69-90.
2. Labrie F., Candas B., Gomez J.L., et al. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology 2002, 60:115-119.
3. Singer E.A., Golijanin D.J., Miyamoto H., et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008, 9:211-228.
4. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 2011, 102:51-56.
5. Akaza H., Hinotsu S., Usami M., et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009, 115:3437-3445.
6. Klotz L., Schellhammer P., Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004, 93:1177-1182.
7. Tammela T.L. Endocrine prevention and treatment of prostate cancer. Mol Cell Endocrinol 2012, 360:59-67.
8. Moreau J.P., Delavault P., Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 2006, 28:1485-1508.
9. Moul J.W., Evans C.P., Gomella L.G., et al. Traditional approaches to androgen deprivation therapy. Urology 2011, 78:S485-S493.
10. Choi S., Lee A.K. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. Drug Healthc Patient Saf 2011, 3:107-119.
11. Labrie F. Medical castration with LHRH agonists: 25years later with major benefits achieved on survival in prostate cancer. J Androl 2004, 25:305-313.
12. Labrie F., Belanger A., Luu-The V., et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005, 26:361-379.
13. Schroder F., Crawford E.D., Axcrona K., et al. Androgen deprivation therapy: past, present and future. BJU Int 2012, 109(Suppl 6):1-12.
14. Lassi K., Dawson N.A. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 2010, 22:263-267.
15. Schellhammer P. Life after failure of traditional androgen deprivation therapy. Urol Oncol 2012, 30:S10-14.
16. Devlin H.L., Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009, 274:177-186.
17. Chi K.N., Bjartell A., Dearnaley D., et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009, 56:594-605.
18. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
19. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
20. Chang S.S., Kibel A.S. The role of systemic cytotoxic therapy for prostate cancer. BJU Int 2009, 103:8-17.
21. Singh P., Yam M., Russell P.J., et al. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett 2010, 293:1-14.
22. Cohen M.B., Rokhlin O.W. Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 2009, 106:363-371.
23. Attard G., Richards J., de Bono J.S. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011, 17:1649-1657.
24. Agarwal N., Sonpavde G., Sternberg C.N. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol 2012, 61:950-960.
25. Felici A., Pino M.S., Carlini P. A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol 2012, 3:1-8.
26. Harrington J.A., Jones R.J. Management of metastatic castration-resistant prostate cancer after first-line docetaxel. Eur J Cancer 2011, 47:2133-2142.
27. Madan R.A., Pal S.K., Sartor O., et al. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011, 17:3892-3902.
28. Antonarakis E.S., Carducci M.A., Eisenberger M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010, 291:1-13.
29. Molina A., Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011, 185:787-794.
30. Osanto S., Van Poppel H. Emerging novel therapies for advanced prostate cancer. Ther Adv Urol 2012, 4:3-12.
31. Payne H., Bahl A., Mason M., et al. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012, 110:658-667.
32. Liu S.V., Schally A.V., Hawes D., et al. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res 2010, 16:4675-4680.
33. Schally A.V., Arimura A., Baba Y., et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971, 43:393-399.
34. Conn P.M., Crowley W.F. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994, 45:391-405.
35. Cheng C.K., Leung P.C. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005, 26:283-306.
36. Millar R.P. GnRHs and GnRH receptors. Anim Reprod Sci 2005, 88:5-28.
37. Harrison G.S., Wierman M.E., Nett T.M., et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004, 11:725-748.
38. Limonta P., Montagnani Marelli M., Mai S. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 2012, 33:784-811.
39. Stopa E.G., Koh E.T., Svendsen C.N., et al. Computer-assisted mapping of immunoreactive mammalian gonadotropin-releasing hormone in adult human basal forebrain and amygdala. Endocrinology 1991, 128:3199-3207.
40. Seeburg P.H., Mason A.J., Stewart T.A., et al. The mammalian GnRH gene and its pivotal role in reproduction. Recent Prog Horm Res 1987, 43:69-98.
41. Hayflick J.S., Adelman J.P., Seeburg P.H. The complete nucleotide sequence of the human gonadotropin-releasing hormone gene. Nucleic Acids Res 1989, 17:6403-6404.
42. Radovick S., Wondisford F.E., Nakayama Y., et al. Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta. Mol Endocrinol 1990, 4:476-480.
43. Millar R.P., Lu Z.L., Pawson A.J., et al. Gonadotropin-releasing hormone receptors. Endocr Rev 2004, 25:235-275.
44. Neill J.D. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002, 143:737-743.
45. Stojilkovic S.S., Reinhart J., Catt K.J. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994, 15:462-499.
46. Kakar S.S., Malik M.T., Winters S.J., et al. Gonadotropin-releasing hormone receptors: structure, expression, and signaling transduction. Vitam Horm 2004, 69:151-207.
47. Kakar S.S., Musgrove L.C., Devor D.C., et al. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 1992, 189:289-295.
48. Rispoli L.A., Nett T.M. Pituitary gonadotropin-releasing hormone (GnRH) receptor: structure, distribution and regulation of expression. Anim Reprod Sci 2005, 88:57-74.
49. Fan N.C., Jeung E.B., Peng C., et al. The human gonadotropin-releasing hormone (GnRH) receptor gene: cloning, genomic organization and chromosomal assignment. Mol Cell Endocrinol 1994, 103:R1-6.
50. Kaiser U.B., Conn P.M., Chin W.W. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 1997, 18:46-70.
51. Davidson J.S., Wakefield I.K., Millar R.P. Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor. Biochem J 1994, 300(Pt 2):299-302.
52. Hislop J.N., Madziva M.T., Everest H.M., et al. Desensitization and internalization of human and xenopus gonadotropin-releasing hormone receptors expressed in alphaT4 pituitary cells using recombinant adenovirus. Endocrinology 2000, 141:4564-4575.
53. McArdle C.A., Franklin J., Green L., et al. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 2002, 173:1-11.
54. Kraus S., Naor Z., Seger R. Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 2001, 32:499-509.
55. Ruf F., Fink M.Y., Sealfon S.C. Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Front Neuroendocrinol 2003, 24:181-199.
56. Naor Z. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol 2009, 30:10-29.
57. McArdle C.A. Gonadotropin-releasing hormone receptor signaling: biased and unbiased. Mini Rev Med Chem 2012, 12:841-850.
58. Dwyer A.A., Hayes F.J., Plummer L., et al. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2010, 95:4235-4243.
59. Han T.S., Bouloux P.M. What is the optimal therapy for young males with hypogonadotropic hypogonadism?. Clin Endocrinol (Oxf) 2010, 72:731-737.
60. Emons G., Schally A.V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994, 9:1364-1379.
61. Maheshwari A., Gibreel A., Siristatidis C.S., et al. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011, CD006919.
62. Magon N. Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab 2011, 15:261-267.
63. Ajossa S., Guerriero S., Paoletti A.M., et al. The treatment of polycystic ovary syndrome. Minerva Ginecol 2004, 56:15-26.
64. Herbst K.L. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003, 3:660-666.
65. Coccia M.E., Comparetto C., Bracco G.L., et al. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004, 115(Suppl 1):S44-56.
66. Huirne J.A., Homburg R., Lambalk C.B. Are GnRH antagonists comparable to agonists for use in IVF?. Hum Reprod 2007, 22:2805-2813.
67. Limonta P., Moretti R.M., Marelli M.M., et al. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 2003, 24:279-295.
68. Marelli M.M., Moretti R.M., Januszkiewicz-Caulier J., et al. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?. Curr Cancer Drug Targets 2006, 6:257-269.
69. Limonta P. Montagnani Marelli M, Moretti RM, LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001, 10:709-720.
70. Schally A.V., Comaru-Schally A.M., Nagy A., et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001, 22:248-291.
71. Klijn J.G., Beex L.V., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000, 92:903-911.
72. Emons G., Ortmann O., Teichert H.M., et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996, 78:1452-1460.
73. Engel J.B., Schally A.V. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007, 3:157-167.
74. Grundker C., Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003, 1:65.
75. Grundker C., Gunthert A.R., Westphalen S., et al. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002, 146:1-14.
76. Mezo G., Manea M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv 2010, 7:79-96.
77. Mezo G., Manea M., Szabi I., et al. New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008, 15:2366-2379.
78. King J.A., Millar R.P. Comparative aspects of luteinizing hormone-releasing hormone structure and function in vertebrate phylogeny. Endocrinology 1980, 106:707-717.
79. Chen A., Yahalom D., Ben-Aroya N., et al. A second isoform of gonadotropin-releasing hormone is present in the brain of human and rodents. FEBS Lett 1998, 435:199-203.
80. White R.B., Eisen J.A., Kasten T.L., et al. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998, 95:305-309.
81. Kang S.K., Tai C.J., Nathwani P.S., et al. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells. Endocrinology 2001, 142:182-192.
82. Leung P.C., Cheng C.K., Zhu X.M. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 2003, 202:145-153.
83. Kauffman A.S. Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour. J Neuroendocrinol 2004, 16:794-806.
84. Pawson A.J., Morgan K., Maudsley S.R., et al. Type II gonadotrophin-releasing hormone (GnRH-II) in reproductive biology. Reproduction 2003, 126:271-278.
85. Cheon K.W., Lee H.S., Parhar I.S., et al. Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle. Mol Hum Reprod 2001, 7:447-452.
86. Neill J.D., Duck L.W., Sellers J.C., et al. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 2001, 282:1012-1018.
87. Millar R., Lowe S., Conklin D., et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 2001, 98:9636-9641.
88. Neill J.D., Musgrove L.C., Duck L.W. Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab 2004, 15:383-392.
89. Faurholm B., Millar R.P., Katz A.A. The genes encoding the type II gonadotropin-releasing hormone receptor and the ribonucleoprotein RBM8A in humans overlap in two genomic loci. Genomics 2001, 78:15-18.
90. Grundker C., Gunthert A.R., Millar R.P., et al. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002, 87:1427-1430.
91. Kim K.Y., Choi K.C., Park S.H., et al. Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2004, 893020-893026.
92. Gunthert A.R., Grundker C., Olota A., et al. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 2005, 153:613-625.
93. Montagnani Marelli M., Moretti R.M., Mai S., et al. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab 2009, 94:1761-1767.
94. Park D.W., Choi K.C., MacCalman C.D., et al. Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase. Reprod Biol Endocrinol 2009, 7:81.
95. Kim K.Y., Choi K.C., Park S.H., et al. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 2005, 90:1670-1677.
96. Kim K.Y., Choi K.C., Auersperg N., et al. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 2006, 13:211-220.
97. Sower S.A., Chiang Y.C., Lovas S., et al. Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinology 1993, 132:1125-1131.
98. Deragon K.L., Sower S.A. Effects of lamprey gonadotropin-releasing hormone-III on steroidogenesis and spermiation in male sea lampreys. Gen Comp Endocrinol 1994, 95:363-367.
99. Lovas S., Palyi I., Vincze B., et al. Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 1998, 52:384-389.
100. Kovacs M., Seprodi J., Koppan M., et al. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol 2002, 14:647-655.
101. Kovacs M., Vincze B., Horvath J.E., et al. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs. Peptides 2007, 28:821-829.
102. Sealfon S.C., Weinstein H., Millar R.P. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997, 18:180-205.
103. Molineaux C.J., Lasdun A., Michaud C., et al. Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo. J Neurochem 1988, 51:624-633.
104. Redding T.W., Kastin A.J., Gonzales-Barcena D., et al. The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin Endocrinol Metab 1973, 37:626-631.
105. Schally A.V., Coy D.H., Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet 1980, 18:318-324.
106. Karten M.J., Rivier J.E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986, 7:44-66.
107. Padula A.M. GnRH analogues - agonists and antagonists. Anim Reprod Sci 2005, 88:115-126.
108. Mezo G., Manea M. Luteinizing hormone-releasing hormone antagonists. Expert Opin Ther Pat 2009, 19:1771-1785.
109. Tan O., Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr Opin Obstet Gynecol 2011, 23:238-244.
110. Huirne J.A., Lambalk C.B. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001, 358:1793-1803.
111. Schally A.V. LH-RH analogues: I. Their impact on reproductive medicine. Gynecol Endocrinol 1999, 13:401-409.
112. Schmidt F., Sundaram K., Thau R.B., et al. [Ac-d-NAL(2)1,4Fd-Phe2, d-Trp3, d-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 1984, 29:283-289.
113. Liu S.V., Liu S., Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011, 20:769-778.
114. Festuccia C., Dondi D., Piccolella M., et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate 2010, 70:1340-1349.
115. Cox M.C., Scripture C.D., Figg W.D. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Rev Anticancer Ther 2005, 5:605-611.
116. Sethi R., Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 2009, 4:259-267.
117. Asch R.H., Rojas F.J., Tice T.R., et al. Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle. Int J Fertil 1985, 30:19-26.
118. Redding T.W., Schally A.V., Tice T.R., et al. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci USA 1984, 81:5845-5848.
119. Crawford E.D., Phillips J.M. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res 2011, 3:201-209.
120. Crawford E.D., Sartor O., Chu F., et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006, 175:533-536.
121. Spitz A., Young J.M., Larsen L., et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis 2012, 15:93-99.
122. Lundstrom E.A., Rencken R.K., van Wyk J.H., et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig 2009, 29:757-765.
123. Shore N., Cookson M.S., Gittelman M.C. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int 2012, 109:226-232.
124. Whelan P. Triptorelin embonate: a 6-month formulation for prostate cancer. Expert Opin Pharmacother 2010, 11:2929-2932.
125. Hu J.C., Williams S.B., O'Malley A.J., et al. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 2012, 61:1119-1128.
126. Saylor P.J., Keating N.L., Freedland S.J., et al. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs 2011, 71:255-261.
127. Ehdaie B., Atoria C.L., Gupta A., et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2012, 118:3397-3406.
128. Herr H.W., O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743-1746.
129. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
130. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361-2367. discussion 2367.
131. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
132. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238-244.
133. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990, 50:2275-2282.
134. Mottet N., Van Damme J., Loulidi S., et al. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2013, 63:121-122.
135. Huhtaniemi I., White R., McArdle C.A., et al. Will GnRH antagonists improve prostate cancer treatment?. Trends Endocrinol Metab 2009, 20:43-50.
136. Van Poppel H., Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012, 19:594-601.
137. Boccon-Gibod L., van der Meulen E., Persson B.E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011, 3:127-140.
138. Pommerville P.J., de Boer J.G. GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010, 17:5063-5070.
139. Kirby R.S., Fitzpatrick J.M., Clarke N. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int 2009, 104:1580-1584.
140. Schally A.V. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999, 20:1247-1262.
141. Reissmann T., Schally A.V., Bouchard P., et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000, 6:322-331.
142. Debruyne F., Tzvetkov M., Altarac S., et al. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 2010, 76:927-933.
143. Tomera K., Gleason D., Gittelman M., et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001, 165:1585-1589.
144. McLeod D., Zinner N., Tomera K., et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001, 58:756-761.
145. Koch M., Steidle C., Brosman S., et al. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003, 62:877-882.
146. Trachtenberg J., Gittleman M., Steidle C., et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002, 167:1670-1674.
147. Wong S.L., Lau D.T., Baughman S.A., et al. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin Pharmacol 2004, 44:495-502.
148. Garnick M.B., Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int 2012, 110:499-504.
149. Mongiat-Artus P., Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004, 5:2171-2179.
150. Dreicer R., Bajorin D.F., McLeod D.G., et al. New data, new paradigms for treating prostate cancer patients - VI: novel hormonal therapy approaches. Urology 2011, 78:S494-498.
151. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009, 31(Pt 2):2312-2331.
152. Shore N.D., Abrahamsson P.A., Anderson J., et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis 2012, 10.1038/pcan.2012.25.
153. Damber J.E., Tammela T.L., Iversen P., et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology 2012, 80:174-181.
154. Crawford E.D., Tombal B., Miller K., et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011, 186:889-897.
155. Jiang G., Stalewski J., Galyean R., et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001, 44:453-467.
156. Princivalle M., Broqua P., White R., et al. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007, 320:1113-1118.
157. Broqua P., Riviere P.J., Conn P.M., et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002, 301:95-102.
158. Koechling W., Hjortkjaer R., Tanko L.B. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 2010, 70:580-587.
159. Gittelman M., Pommerville P.J., Persson B.E., et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008, 180:1986-1992.
160. Van Poppel H., Tombal B., de la Rosette J.J., et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008, 54:805-813.
161. Klotz L., Boccon-Gibod L., Shore N.D., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008, 102:1531-1538.
162. Ulmert D., Vickers A.J., Scher H.I., et al. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clin Chem Lab Med 2012, 1-6.
163. Axcrona K., Aaltomaa S., da Silva C.M., et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 2012, 110:1721-1728.
164. Smith M.R., Klotz L., van der Meulen E., et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011, 186:1835-1842.
165. Iversen P., Karup C., van der Meulen E., et al. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. Prostate Cancer Prostatic Dis 2011, 14:184-190.
166. de la Rosette J., Davis R., Frankel D., et al. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract 2011, 65:559-566.
167. Pelletier J.C., Chengalvala M., Cottom J., et al. 2-Phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem 2008, 16:6617-6640.
168. Betz S.F., Zhu Y.F., Chen C., et al. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem 2008, 51:3331-3348.
169. Anderes K.L., Luthin D.R., Castillo R., et al. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther 2003, 305:688-695.
170. Barnes M.J., Burschka C., Buttner M.W., et al. Silicon analogues of the nonpeptidic GnRH antagonist AG-045572: syntheses, crystal structure analyses, and pharmacological characterization. ChemMedChem 2011, 6:2070-2080.
171. Volker P., Grundker C., Schmidt O., et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002, 186:171-179.
172. Imai A., Ohno T., Iida K., et al. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994, 55:144-148.
173. Baumann K.H., Kiesel L., Kaufmann M., et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993, 25:37-46.
174. Limonta P., Dondi D., Moretti R.M., et al. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993, 76:797-800.
175. Dondi D., Limonta P., Moretti R.M., et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994, 54:4091-4095.
176. Srkalovic G., Bokser L., Radulovic S., et al. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990, 127:3052-3060.
177. Limonta P., Moretti R.M., Marelli M.M., et al. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999, 140:5250-5256.
178. Halmos G., Arencibia J.M., Schally A.V., et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000, 163:623-629.
179. Straub B., Muller M., Krause H., et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001, 7:2340-2343.
180. Straub B., Muller M., Krause H., et al. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003, 62:172-176.
181. Szabo J., Vegh A., Racz G., et al. Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma. Urol Oncol 2005, 23:399-401.
182. Gnanapragasam V.J., Darby S., Khan M.M., et al. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 2005, 206:205-213.
183. Tieva A., Stattin P., Wikstrom P., et al. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001, 47:276-284.
184. Bono A.V., Salvadore M., Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002, 24:221-227.
185. Moretti R.M., Monagnani Marelli M., van Groeninghen J.C., et al. Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 2003, 10:161-167.
186. Moretti R.M., Mai S., Montagnani Marelli M., et al. Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis. Endocrinology 2010, 151:4643-4653.
187. Imai A., Horibe S., Takagi H., et al. Signal transduction of GnRH receptor in the reproductive tract tumor. Endocr J 1996, 43:249-260.
188. Imai A., Takagi H., Furui T., et al. Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 1996, 77:132-137.
189. Maudsley S., Davidson L., Pawson A.J., et al. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004, 64:7533-7544.
190. Morgan K., Stavrou E., Leighton S.P., et al. Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells. Prostate 2011, 71:915-928.
191. Kraus S., Naor Z., Seger R. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett 2006, 234:109-123.
192. Kraus S., Levy G., Hanoch T., et al. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 2004, 64:5736-5744.
193. Paweletz C.P., Charboneau L., Bichsel V.E., et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989.
194. Malik S.N., Brattain M., Ghosh P.M., et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002, 8:1168-1171.
195. Graff J.R., Konicek B.W., McNulty A.M., et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000, 275:24500-24505.
196. Montagnani Marelli M., Moretti R.M., Mai S., et al. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 2007, 30:261-271.
197. Yates C., Wells A., Turner T. Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 2005, 92:366-375.
198. Moretti R.M., Marelli M.M., Dondi D., et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996, 81:3930-3937.
199. Marelli M.M., Moretti R.M., Dondi D., et al. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 1999, 140:329-334.
200. Imai A., Tamaya T. GnRH receptor and apoptotic signaling. Vitam Horm 2000, 59:1-33.
201. Cheung L.W., Wong A.S. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 2008, 275:5479-5495.
202. Limonta P., Dondi D., Moretti R.M., et al. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992, 75:207-212.
203. Dondi D., Moretti R.M., Montagnani Marelli M., et al. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 1998, 76:506-511.
204. Franklin J., Hislop J., Flynn A., et al. Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. J Endocrinol 2003, 176:275-284.
205. Wells A., Souto J.C., Solava J., et al. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res 2002, 8:1251-1257.
206. Clementi M., Sanchez C., Benitez D.A., et al. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate 2009, 69:1025-1033.
207. Castellon E., Clementi M., Hitschfeld C., et al. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 2006, 24:261-268.
208. Dondi D., Festuccia C., Piccolella M., et al. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 2006, 15:393-400.
209. Enomoto M., Utsumi M., Park M.K. Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 2006, 147:530-542.
210. Lawrentschuk N., Fernandes K., Bell D., et al. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 2011, 185:848-854.
211. Millar R.P., Pawson A.J., Morgan K., et al. Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol 2008, 29:17-35.
212. Millar R.P., Pawson A.J. Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment. Endocrinology 2004, 145:3590-3593.
213. Jungwirth A., Pinski J., Galvan G., et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997, 33:1141-1148.
214. Jungwirth A., Galvan G., Pinski J., et al. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997, 32:164-172.
215. Lamharzi N., Schally A.V., Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 1998, 77:185-192.
216. Masson-Lecomte A., Guy L., Pedron P., et al. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. World J Urol 2012, 10.1007/s00345-012-0841-1.
217. Grundker C., Schlotawa L., Viereck V., et al. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004, 151:141-149.
218. Darby S., Stockley J., Khan M.M., et al. Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocr Relat Cancer 2007, 14:613-624.
219. Maiti K., Oh D.Y., Moon J.S., et al. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J Clin Endocrinol Metab 2005, 90:4287-4298.
220. Kim D.K., Yang J.S., Maiti K., et al. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 2009, 69:923-931.
221. Enomoto M., Park M.K. GnRH as a cell proliferation regulator: mechanism of action and evolutionary implications. Zoolog Sci 2004, 21:1005-1013.
222. Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
223. Janaky T., Juhasz A., Bajusz S., et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 1992, 89:972-976.
224. Pinski J., Schally A.V., Yano T., et al. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 1993, 23:165-178.
225. Nagy A., Schally A.V., Armatis P., et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996, 93:7269-7273.
226. Bajusz S., Janaky T., Csernus V.J., et al. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1989, 86:6313-6317.
227. Nagy A., Schally A.V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005, 73:851-859.
228. Schally A.V., Engel J.B., Emons G., et al. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 2011, 8:11-25.
229. Jungwirth A., Schally A., Nagy A., et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997, 10:877-884.
230. Koppan M., Nagy A., Schally A.V., et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999, 38:151-158.
231. Plonowski A., Schally A.V., Nagy A., et al. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002, 176:57-63.
232. Stangelberger A., Schally A.V., Nagy A., et al. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate 2006, 66:200-210.
233. Letsch M., Schally A.V., Szepeshazi K., et al. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003, 9:4505-4513.
234. Engel J., Emons G., Pinski J., et al. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 2012, 21:891-899.
235. Westphalen S., Kotulla G., Kaiser F., et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000, 17:1063-1069.
236. Gunthert A.R., Grundker C., Bongertz T., et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004, 191:1164-1172.
237. Gunthert A.R., Grundker C., Bongertz T., et al. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Res Treat 2004, 87:255-264.
238. Nagy A., Plonowski A., Schally A.V. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA 2000, 97:829-834.
239. Grundker C. Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy. Eur J Endocrinol 2000, 143:569-572.
240. Sundaram S., Durairaj C., Kadam R., et al. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 2009, 8:1655-1665.
241. Mezo I., Lovas S., Palyi I., et al. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. J Med Chem 1997, 40:3353-3358.
242. Szabo I., Manea M., Orban E., et al. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009, 20:656-665.
243. Orban E., Mezo G., Schlage P., et al. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 2011, 41:469-483.
244. Schlage P., Mezo G., Orban E., et al. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J Control Release 2011, 156:170-178.
245. Manea M., Tovari J., Tejeda M., et al. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice. Anticancer Drugs 2012, 23:90-97.
246. Manea M., Leurs U., Orban E., et al. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4. Bioconjug Chem 2011, 22:1320-1329.
247. Hegedus R., Manea M., Orban E., et al. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates. Eur J Med Chem 2012, 56:155-165.
248. Leurs U., Lajko E., Mezo G., et al. GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. Eur J Med Chem 2012, 52:173-183.
249. Leurs U., Mezo G., Orban E., et al. Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety. Biopolymers 2012, 98:1-10.
250. Shin S.Y., Kang J.H., Jang S.Y., et al. Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells. Biochim Biophys Acta 2000, 1463:209-218.
251. Leuschner C., Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004, 10:2299-2310.
252. Leuschner C., Enright F.M., Gawronska-Kozak B., et al. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003, 56:239-249.
253. Hansel W., Leuschner C., Enright F. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007, 269:26-33.
254. Yates C., Sharp S., Jones J., et al. LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochem Pharmacol 2011, 81:104-110.
255. Qi L., Nett T.M., Allen M.C., et al. GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines. Urol Res 2003, 31:374-377.
256. Yang W.H., Wieczorck M., Allen M.C., et al. Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 2003, 144:1456-1463.
257. Qi L., Nett T.M., Allen M.C., et al. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res 2004, 64:2090-2095.